An increase in circulating amino acid levels overloads functioning of kidneys by increasing glomerular filtration rate, an indicator of kidney function in humans. Hence a sustained intake of excess dietary protein likely accelerates the progression of kidney failure. In addition, elevated blood amino acid levels induce insulin resistance, leading to metabolic abnormalities in humans. Therefore, we focused on inhibiting gut amino acid intake into the circulation to improve kidney function and metabolic disease.

Enteropeptidase is a gut-localized pivotal enzyme that activates protein digestion events in mammals. We identified SCO-792, an orally available enteropeptidase inhibitor with first-in-class potential, that can inhibit gut amino acid intake into the circulation. SCO-792 treatment improves kidney and metabolic parameters in preclinical models of diabetic kidney disease (DKD) and chronic kidney disease.

In a phase 2 proof-of-concept study, 12-week treatment with SCO-792 resulted in a clinically significant reduction in the urine albumin-to-creatinine ratio from baseline in patients with DKD. In addition, SCO-792 treatment was associated with decreased HbA1c and fasting glucose levels.

SCOHIA is actively seeking partnerships worldwide for the development and commercialization of SCO-792 (Contact here for partnering).


  • Diabetic kidney disease
  • Chronic kidney disease
  • Diabetes